We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > iRhom2

News List

SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases B3C newswire
November 16, 2023
SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline.
SciRhom Establishes a World-Class Clinical Advisory Board B3Cnewswire
December 16, 2021
SciRhom GmbH, an advanced startup dedicated to developing transformative therapies for autoimmune diseases, today announced the appointment of their Clinical Advisory Board.
SciRhom Augments Seed Financing to Reach Total Funding of EUR 16 Million B3Cnewswire
December 01, 2021
SciRhom GmbH, a developer of novel antibody therapies, announced today an increase of their seed capital by EUR 8 million. With this added investment, the company has secured a total of EUR 16 million...
SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases b3cnewswire
November 06, 2019
SciRhom GmbH, a therapeutic antibody company, announced the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways ...